Download App

Log in to access Online Inquiry
Company Overview More
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
CEO: Cohen-Dayag Ph.D., Anat
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > CGEN Compugen > Detailed Quotes

CGEN Compugen

1.940+0.010+0.52%
Close 05/19 20:00 ET
1.94000.00%
Pre Mkt Price 05/20 04:00 ET
High
2.010
Open
1.870
Turnover
1.74M
Low
1.850
Pre Close
1.930
Volume
898.91K
Market Cap
167.73M
P/E(TTM)
Loss
52wk High
9.200
Shares
86.46M
P/E(Static)
Loss
52wk Low
1.660
Float Cap
158.35M
Bid/Ask %
-75.00%
Historical High
19.900
Shs Float
81.62M
Volume Ratio
0.78
Historical Low
0.340
Dividend TTM
--
Div Yield TTM
--
P/B
1.71
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.10%
Amplitude
8.29%
Avg Price
1.936
Lot Size
1
Float Cap
158.35M
Bid/Ask %
-75.00%
Historical High
19.900
Shs Float
81.62M
Volume Ratio
0.78
Historical Low
0.340
Dividend TTM
--
P/B
1.71
Dividend LFY
--
Turnover Ratio
1.10%
Amplitude
8.29%
Avg Price
1.936
Lot Size
1
Price Forecast

No Data

News

Comment